ReviewAdvances in therapy2017
Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.
Review in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Anti-vascular endothelial growth factor for neovascular glaucoma.The Cochrane database of systematic reviews · 2023Pooled it
- Pooled it
- Downregulation of angiogenic factors in aqueous humor associated with less intraoperative bleeding in PDR patients with NVG receiving conbercept: a randomized controlled trial.BMC ophthalmology · 2022Trial
- Clinical outcomes and safety profile of glaucoma drainage device Ahmed ClearPath® 250 mmInternational journal of ophthalmology · 2025Article
- DPP-4 Inhibitors Attenuate Fibrosis After Glaucoma Filtering Surgery by Suppressing the TGF-β/Smad Signaling Pathway.Investigative ophthalmology & visual science · 2023Article
- Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity.Arquivos brasileiros de oftalmologia · 2023Observational
- Article
- Intravitreal anti-vascular endothelial growth factor injections to treat post-trabeculectomy Swan syndrome.American journal of ophthalmology case reports · 2022Article
- Clinical research of EX-PRESS drainage device and modified trabeculectomy combined with intravitreal conbercept treatment for neovascular glaucoma.International journal of ophthalmology · 2022Article
- The Effect of a Triple Combination of Bevacizumab, Sodium Hyaluronate and a Collagen Matrix Implant in a Trabeculectomy Animal Model.Pharmaceutics · 2021Article
- The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma.Frontiers in medicine · 2021Article
- Intracameral anti-VEGF injection for advanced neovascular glaucoma after vitrectomy with silicone oil tamponade.International journal of ophthalmology · 2021Article
- Role of bevacizumab intraocular injection in the management of neovascular glaucoma.International journal of ophthalmology · 2021Article
- Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective.International journal of nanomedicine · 2021Review
- Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions.Pharmaceutics · 2020Review
- Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies.Journal of clinical medicine · 2020Review
- Retinal Cell Protection in Ocular Excitotoxicity Diseases. Possible Alternatives Offered by Microparticulate Drug Delivery Systems and Future Prospects.Pharmaceutics · 2020Review
- A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach.Naunyn-Schmiedeberg's archives of pharmacology · 2019Review
- Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma.International journal of ophthalmology · 2019Article
- Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.